Analyst downgrades Genomic stock

03/7/2006 | MSN Money

Genomic Health's only product, the Oncotype DX test for evaluating breast cancer relapse risk and early-stage cancer patients' response to chemotherapy, might be deemed a Class III medical device by the FDA, according to an analyst. As a result of the increased regulatory risk, the stock was downgraded and the price target was lowered.

View Full Article in:

MSN Money

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR